Search for Clinical Trial Results

Sponsored By

Hemangioblastoma - 22 Studies Found

Status Study
Terminated Study Name: Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease
Condition:
  • Hemangioblastomas
  • Von Hippel Lindau Disease

Date: 2009-11-16
Interventions: Drug: Avastin Patients will receive Bevacizumab (Avastin) 10mg/kg IV every two weeks for 6 months
Completed Study Name: Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
Condition:
  • Von Hippel-Lindau Disease
  • CNS Hemangioblastoma
  • Hemangioblastoma (HB) of the Central Nervous System (CNS)
    Date: 2014-04-16
    Interventions: Other: evaluation of anxiety with psychosocial scales
Active, not recruiting Study Name: Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease
Condition:
  • Hemangioblastoma
  • Hippel Lindau Disease

Date: 2000-06-06
Enrolling by invitation Study Name: Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)
Condition: Von Hippel-Lindau Disease
Date: 2014-04-05
Interventions: Drug: Vorinostat
Terminated Study Name: Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow
Condition:
  • Von Hippel-Lindau Syndrome
  • Renal Cell Carcinoma
  • Date: 2006-05-26
    Interventions: Drug: SU011248 50 mg/day orally for 4 weeks, no treatment for 2 weeks (6 weeks = 1 cycle).
Completed Study Name: Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
Condition:
  • CNS Cancer
  • Meningioma
  • Intracranial Hemangiopericytoma

    • Date: 2007-12-26
    Interventions: Drug: Sunitinib The study drug will be administered on an outpatient basis. The starting dose will be 50
Completed Study Name: Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
Condition: